Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
True, sustainable recovery happens in the partnership between the clinical tool and the therapeutic work
In a Mayo Clinic study presented at an annual meeting of the Endocrine Society in July 2025, researchers found that, over 18 months, 40 postmenopausal women who combined the GLP-1 drug tirzepatide (used in Mounjaro and Zepbound) with hormone therapy lost an average of 17 percent of their body weight
The risk of hypoglycemia, or low blood sugar, is very low and usually only occurs in patients who take a GLP-1 medication with another medication that is known to cause hypoglycemia, such as insulin
We accept insurance, handle prior authorization, and provide ongoing care coordination so you can focus on your health
US$ 28.55
US$ 26.31
US$ 23.19
